With Gilead and AbbVie posting essentially perfect phase 2 data with their hepatitis-C treatments, the bar has been set very high for those looking to join the race. To that end, Achillion shares are under pressure today after releasing interim data for one of its NS5A inhibitors targeting the disease. As Brenton Flynn discusses in the following video, this severe reaction to such a small data set reflects the paradigm shift in investor expectations around hepatitis-C treatments.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.